JP6893265B2 - Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法 - Google Patents

Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法 Download PDF

Info

Publication number
JP6893265B2
JP6893265B2 JP2020036331A JP2020036331A JP6893265B2 JP 6893265 B2 JP6893265 B2 JP 6893265B2 JP 2020036331 A JP2020036331 A JP 2020036331A JP 2020036331 A JP2020036331 A JP 2020036331A JP 6893265 B2 JP6893265 B2 JP 6893265B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
asthma
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020036331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020105193A5 (enrdf_load_stackoverflow
JP2020105193A (ja
Inventor
ジャンルカ・ピロッジ
フランク・スコビエランダ
ヨンタオ・リー
ニール・グレアム
スティーヴン・ピー・ワインスタイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2016552595A external-priority patent/JP6673840B2/ja
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2020105193A publication Critical patent/JP2020105193A/ja
Publication of JP2020105193A5 publication Critical patent/JP2020105193A5/ja
Priority to JP2021089717A priority Critical patent/JP7343547B2/ja
Application granted granted Critical
Publication of JP6893265B2 publication Critical patent/JP6893265B2/ja
Priority to JP2023139455A priority patent/JP7636487B2/ja
Priority to JP2025020415A priority patent/JP2025072593A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2020036331A 2014-02-21 2020-03-04 Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法 Active JP6893265B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021089717A JP7343547B2 (ja) 2014-02-21 2021-05-28 Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP2023139455A JP7636487B2 (ja) 2014-02-21 2023-08-30 Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP2025020415A JP2025072593A (ja) 2014-02-21 2025-02-12 Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461943019P 2014-02-21 2014-02-21
US61/943,019 2014-02-21
EP14306413 2014-09-15
EP14306413.7 2014-09-15
US201462077669P 2014-11-10 2014-11-10
US62/077,669 2014-11-10
JP2016552595A JP6673840B2 (ja) 2014-02-21 2015-02-20 Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016552595A Division JP6673840B2 (ja) 2014-02-21 2015-02-20 Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021089717A Division JP7343547B2 (ja) 2014-02-21 2021-05-28 Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法

Publications (3)

Publication Number Publication Date
JP2020105193A JP2020105193A (ja) 2020-07-09
JP2020105193A5 JP2020105193A5 (enrdf_load_stackoverflow) 2020-11-19
JP6893265B2 true JP6893265B2 (ja) 2021-06-23

Family

ID=66624883

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020036331A Active JP6893265B2 (ja) 2014-02-21 2020-03-04 Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP2021089717A Active JP7343547B2 (ja) 2014-02-21 2021-05-28 Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021089717A Active JP7343547B2 (ja) 2014-02-21 2021-05-28 Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法

Country Status (2)

Country Link
JP (2) JP6893265B2 (enrdf_load_stackoverflow)
IL (2) IL247290B (enrdf_load_stackoverflow)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JP2014533246A (ja) * 2011-11-01 2014-12-11 メディミューン，エルエルシー 喘息の急性増悪の頻度および重症度を低下させる方法
HUE064945T2 (hu) * 2012-08-21 2024-04-28 Sanofi Biotechnology Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával

Also Published As

Publication number Publication date
JP7343547B2 (ja) 2023-09-12
IL247290B (en) 2021-06-30
IL247290A0 (en) 2016-09-29
JP2021130695A (ja) 2021-09-09
IL283422A (en) 2021-06-30
JP2020105193A (ja) 2020-07-09

Similar Documents

Publication Publication Date Title
JP7636487B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
AU2022201336B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
US20220204631A1 (en) Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
JP2021501169A (ja) Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP2022530533A (ja) Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法
JP6893265B2 (ja) Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法
CN114786775A (zh) 通过施用il-33拮抗剂治疗copd的方法
HK40070002A (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
HK40070002B (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
HK1231767B (en) Methods for treating or preventing asthma by administering an il-4r antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210506

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210531

R150 Certificate of patent or registration of utility model

Ref document number: 6893265

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250